AIMS: To evaluate short-term clinical outcomes following transcatheter aortic valve implantation (TAVI) using CE-mark approved devices in Switzerland. METHODS AND RESULTS: The Swiss TAVI registry is a national, prospective, multicentre, monitored cohort study evaluating clinical outcomes in consecutive patients undergoing TAVI at cardiovascular centres in Switzerland. From February 2011 to March 2013, a total of 697 patients underwent TAVI for native aortic valve stenosis (98.1%), degenerative aortic bioprosthesis (1.6%) or severe aortic regurgitation (0.3%). Patients were elderly (82.4±6 years), 52% were females, and the majority highly symptomatic (73.1% NYHA III/IV). Patients with severe aortic stenosis (mean gradient 44.8±17 mmHg, aortic valve area 0.7±0.3 cm²) were either deemed inoperable or at high risk for conventional surgery (STS 8.2%±7). The transfemoral access was the most frequently used (79.1%), followed by transapical (18.1%), direct aortic (1.7%) and subclavian access (1.1%). At 30 days, rates of all-cause mortality, cerebrovascular events and myocardial infarction were 4.8%, 3.3% and 0.4%, respectively. The most frequently observed adverse events were access-related complications (11.8%), permanent pacemaker implantation (20.5%) and bleeding complications (16.6%). The Swiss TAVI registry is registered at ClinicalTrials.gov (NCT01368250). CONCLUSIONS: The Swiss TAVI registry is a national cohort study evaluating consecutive TAVI procedures in Switzerland. This first outcome report provides favourable short-term clinical outcomes in unselected TAVI patients.
AIMS: To evaluate short-term clinical outcomes following transcatheter aortic valve implantation (TAVI) using CE-mark approved devices in Switzerland. METHODS AND RESULTS: The Swiss TAVI registry is a national, prospective, multicentre, monitored cohort study evaluating clinical outcomes in consecutive patients undergoing TAVI at cardiovascular centres in Switzerland. From February 2011 to March 2013, a total of 697 patients underwent TAVI for native aortic valve stenosis (98.1%), degenerative aortic bioprosthesis (1.6%) or severe aortic regurgitation (0.3%). Patients were elderly (82.4±6 years), 52% were females, and the majority highly symptomatic (73.1% NYHA III/IV). Patients with severe aortic stenosis (mean gradient 44.8±17 mmHg, aortic valve area 0.7±0.3 cm²) were either deemed inoperable or at high risk for conventional surgery (STS 8.2%±7). The transfemoral access was the most frequently used (79.1%), followed by transapical (18.1%), direct aortic (1.7%) and subclavian access (1.1%). At 30 days, rates of all-cause mortality, cerebrovascular events and myocardial infarction were 4.8%, 3.3% and 0.4%, respectively. The most frequently observed adverse events were access-related complications (11.8%), permanent pacemaker implantation (20.5%) and bleeding complications (16.6%). The Swiss TAVI registry is registered at ClinicalTrials.gov (NCT01368250). CONCLUSIONS: The Swiss TAVI registry is a national cohort study evaluating consecutive TAVI procedures in Switzerland. This first outcome report provides favourable short-term clinical outcomes in unselected TAVI patients.
Authors: G Biondi-Zoccai; M Peruzzi; A Abbate; Z M Gertz; U Benedetto; E Tonelli; F D'Ascenzo; A Giordano; P Agostoni; G Frati Journal: Heart Lung Vessel Date: 2014
Authors: G Krasopoulos; F Falconieri; U Benedetto; J Newton; R Sayeed; R Kharbanda; A Banning Journal: J Cardiothorac Surg Date: 2016-11-29 Impact factor: 1.637
Authors: Andrea Ungar; Giulio Mannarino; Nathalie van der Velde; Jan Baan; Marie-Pierre Thibodeau; Jean-Bernard Masson; Gennaro Santoro; Martijn van Mourik; Sofie Jansen; Cornelia Deutsch; Peter Bramlage; Jana Kurucova; Martin Thoenes; Stefania Maggi; Andreas W Schoenenberger Journal: BMC Cardiovasc Disord Date: 2018-01-04 Impact factor: 2.298
Authors: Marek Kowalski; Cornelia Deutsch; Steffen Hofmann; Norbert Franz; Michael Billion; Abbas Ferdosi; Peter Bramlage; Guram Imnadze; Henning Warnecke Journal: Kardiochir Torakochirurgia Pol Date: 2017-12-20
Authors: Thomas Pilgrim; Stefan Stortecky; Fabian Nietlispach; Dik Heg; David Tueller; Stefan Toggweiler; Enrico Ferrari; Stéphane Noble; Francesco Maisano; Raban Jeger; Marco Roffi; Jürg Grünenfelder; Christoph Huber; Peter Wenaweser; Stephan Windecker Journal: J Am Heart Assoc Date: 2016-11-17 Impact factor: 5.501